MEDF — Medfield Diagnostics AB Income Statement
0.000.00%
Last trade - 00:00- SEK14.28m
- SEK11.65m
- SEK0.71m
Annual income statement for Medfield Diagnostics AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | SAS | SAS | SAS | SAS | SAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.854 | 1.2 | 0.4 | 2.4 | 0.713 |
| Cost of Revenue | |||||
| Gross Profit | 3.79 | 5.83 | 7.15 | 8.27 | 5.46 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 8.94 | 8.46 | 7.66 | 10.8 | 14.6 |
| Operating Profit | -8.08 | -7.26 | -7.26 | -8.38 | -13.9 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -8.09 | -7.26 | -7.26 | -8.37 | -15 |
| Net Income After Taxes | -8.09 | -7.26 | -7.26 | -8.37 | -15 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -8.09 | -7.26 | -7.26 | -8.37 | -15 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -8.09 | -7.26 | -7.26 | -8.37 | -15 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.276 | -0.22 | -0.185 | -0.22 | -0.19 |
| Dividends per Share |